Breast Cancer - Pipeline Review, H2 2015

Date: December 31, 2015
Pages: 2995
Price:
US$ 2,500.00 US$ 2,125.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: BA112F0CD07EN
Leaflet:

Download PDF Leaflet

Breast Cancer - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Breast Cancer - Pipeline Review, H2 2015’, provides an overview of the Breast Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Breast Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Breast Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Breast Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Breast Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Breast Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Breast Cancer Overview
Therapeutics Development
Breast Cancer - Therapeutics under Development by Companies
Breast Cancer - Therapeutics under Investigation by Universities/Institutes
Breast Cancer - Pipeline Products Glance
Breast Cancer - Products under Development by Companies
Breast Cancer - Products under Investigation by Universities/Institutes
Breast Cancer - Companies Involved in Therapeutics Development
Breast Cancer - Therapeutics Assessment
Drug Profiles
Breast Cancer - Recent Pipeline Updates 2165
Breast Cancer - Dormant Projects 2820
Breast Cancer - Discontinued Products 2869
Breast Cancer - Product Development Milestones 2880
Appendix 2889

LIST OF TABLES

Number of Products under Development for Breast Cancer, H2 2015
Number of Products under Development for Breast Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Development by Companies, H2 2015 (Contd..8)
Number of Products under Development by Companies, H2 2015 (Contd..9)
Number of Products under Development by Companies, H2 2015 (Contd..10)
Number of Products under Development by Companies, H2 2015 (Contd..11)
Number of Products under Development by Companies, H2 2015 (Contd..12)
Number of Products under Development by Companies, H2 2015 (Contd..13)
Number of Products under Development by Companies, H2 2015 (Contd..14)
Number of Products under Development by Companies, H2 2015 (Contd..15)
Number of Products under Development by Companies, H2 2015 (Contd..16)
Number of Products under Development by Companies, H2 2015 (Contd..17)
Number of Products under Development by Companies, H2 2015 (Contd..18)
Number of Products under Development by Companies, H2 2015 (Contd..19)
Number of Products under Development by Companies, H2 2015 (Contd..20)
Number of Products under Development by Companies, H2 2015 (Contd..21)
Number of Products under Development by Companies, H2 2015 (Contd..22)
Number of Products under Development by Companies, H2 2015 (Contd..23)
Number of Products under Development by Companies, H2 2015 (Contd..24)
Number of Products under Development by Companies, H2 2015 (Contd..25)
Number of Products under Development by Companies, H2 2015 (Contd..26)
Number of Products under Development by Companies, H2 2015 (Contd..27)
Number of Products under Development by Companies, H2 2015 (Contd..28)
Number of Products under Development by Companies, H2 2015 (Contd..29)
Number of Products under Development by Companies, H2 2015 (Contd..30)
Number of Products under Development by Companies, H2 2015 (Contd..31)
Number of Products under Development by Companies, H2 2015 (Contd..32)
Number of Products under Development by Companies, H2 2015 (Contd..33)
Number of Products under Development by Companies, H2 2015 (Contd..34)
Number of Products under Development by Companies, H2 2015 (Contd..35)
Number of Products under Development by Companies, H2 2015 (Contd..36)
Number of Products under Investigation by Universities/Institutes, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..6)
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..7)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Development by Companies, H2 2015 (Contd..12)
Products under Development by Companies, H2 2015 (Contd..13)
Products under Development by Companies, H2 2015 (Contd..14)
Products under Development by Companies, H2 2015 (Contd..15)
Products under Development by Companies, H2 2015 (Contd..16)
Products under Development by Companies, H2 2015 (Contd..17)
Products under Development by Companies, H2 2015 (Contd..18)
Products under Development by Companies, H2 2015 (Contd..19)
Products under Development by Companies, H2 2015 (Contd..20)
Products under Development by Companies, H2 2015 (Contd..21)
Products under Development by Companies, H2 2015 (Contd..22)
Products under Development by Companies, H2 2015 (Contd..23)
Products under Development by Companies, H2 2015 (Contd..24)
Products under Development by Companies, H2 2015 (Contd..25)
Products under Development by Companies, H2 2015 (Contd..26)
Products under Development by Companies, H2 2015 (Contd..27)
Products under Development by Companies, H2 2015 (Contd..28)
Products under Development by Companies, H2 2015 (Contd..29)
Products under Development by Companies, H2 2015 (Contd..30)
Products under Development by Companies, H2 2015 (Contd..31)
Products under Development by Companies, H2 2015 (Contd..32)
Products under Development by Companies, H2 2015 (Contd..33)
Products under Development by Companies, H2 2015 (Contd..34)
Products under Development by Companies, H2 2015 (Contd..35)
Products under Development by Companies, H2 2015 (Contd..36)
Products under Development by Companies, H2 2015 (Contd..37)
Products under Development by Companies, H2 2015 (Contd..38)
Products under Development by Companies, H2 2015 (Contd..39)
Products under Development by Companies, H2 2015 (Contd..40)
Products under Development by Companies, H2 2015 (Contd..41)
Products under Development by Companies, H2 2015 (Contd..42)
Products under Development by Companies, H2 2015 (Contd..43)
Products under Development by Companies, H2 2015 (Contd..44)
Products under Development by Companies, H2 2015 (Contd..45)
Products under Development by Companies, H2 2015 (Contd..46)
Products under Development by Companies, H2 2015 (Contd..47)
Products under Development by Companies, H2 2015 (Contd..48)
Products under Development by Companies, H2 2015 (Contd..49)
Products under Development by Companies, H2 2015 (Contd..50)
Products under Development by Companies, H2 2015 (Contd..51)
Products under Development by Companies, H2 2015 (Contd..52)
Products under Development by Companies, H2 2015 (Contd..53)
Products under Development by Companies, H2 2015 (Contd..54)
Products under Development by Companies, H2 2015 (Contd..55)
Products under Development by Companies, H2 2015 (Contd..56)
Products under Development by Companies, H2 2015 (Contd..57)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..5)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..6)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..7)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..8)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..9)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..10)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..11)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..12)
Breast Cancer - Pipeline by 3-V Biosciences, Inc., H2 2015
Breast Cancer - Pipeline by 4SC AG, H2 2015
Breast Cancer - Pipeline by A&G Pharmaceutical, Inc., H2 2015
Breast Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2015
Breast Cancer - Pipeline by AB Science SA, H2 2015
Breast Cancer - Pipeline by AbbVie Inc., H2 2015
Breast Cancer - Pipeline by AbGenomics International, Inc., H2 2015
Breast Cancer - Pipeline by Ability Pharma, SL, H2 2015
Breast Cancer - Pipeline by Acceleron Pharma, Inc., H2 2015
Breast Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015
Breast Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015
Breast Cancer - Pipeline by Adaptimmune Limited, H2 2015
Breast Cancer - Pipeline by ADC Therapeutics Sarl, H2 2015
Breast Cancer - Pipeline by Aduro BioTech, Inc., H2 2015
Breast Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2015
Breast Cancer - Pipeline by Advanced Proteome Therapeutics Corporation, H2 2015
Breast Cancer - Pipeline by Advaxis, Inc., H2 2015
Breast Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2015
Breast Cancer - Pipeline by Aegis Therapeutics, LLC, H2 2015
Breast Cancer - Pipeline by Aeglea BioTherapeutics, Inc., H2 2015
Breast Cancer - Pipeline by Aerpio Therapeutics, Inc., H2 2015
Breast Cancer - Pipeline by Aeterna Zentaris Inc., H2 2015
Breast Cancer - Pipeline by Affichem SA, H2 2015
Breast Cancer - Pipeline by Agilvax, Inc., H2 2015
Breast Cancer - Pipeline by Aileron Therapeutics, Inc., H2 2015
Breast Cancer - Pipeline by Alchemia Limited, H2 2015
Breast Cancer - Pipeline by Alethia Biotherapeutics Inc., H2 2015
Breast Cancer - Pipeline by Almac Discovery Limited, H2 2015
Breast Cancer - Pipeline by Amarna Therapeutics B.V., H2 2015
Breast Cancer - Pipeline by Ambrx, Inc., H2 2015
Breast Cancer - Pipeline by Amgen Inc., H2 2015
Breast Cancer - Pipeline by Ampio Pharmaceuticals, Inc., H2 2015
Breast Cancer - Pipeline by Amplyx Pharmaceuticals, Inc., H2 2015
Breast Cancer - Pipeline by AngioGenex, Inc., H2 2015
Breast Cancer - Pipeline by Angion Biomedica Corp., H2 2015
Breast Cancer - Pipeline by ANP Technologies, Inc., H2 2015
Breast Cancer - Pipeline by AntiCancer, Inc., H2 2015
Breast Cancer - Pipeline by Antigen Express, Inc., H2 2015
Breast Cancer - Pipeline by Antoxis Limited, H2 2015
Breast Cancer - Pipeline by Aphios Corporation, H2 2015
Breast Cancer - Pipeline by arGEN-X BV, H2 2015
Breast Cancer - Pipeline by Armour Therapeutics Inc., H2 2015
Breast Cancer - Pipeline by Arno Therapeutics, Inc., H2 2015
Breast Cancer - Pipeline by ArQule, Inc., H2 2015
Breast Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H2 2015
Breast Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2015
Breast Cancer - Pipeline by Ascentage Pharma Group Corporation, Ltd., H2 2015
Breast Cancer - Pipeline by AskAt Inc., H2 2015
Breast Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2015
Breast Cancer - Pipeline by Astellas Pharma Inc., H2 2015
Breast Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
Breast Cancer - Pipeline by AstraZeneca Plc, H2 2015

LIST OF FIGURES

Number of Products under Development for Breast Cancer, H2 2015
Number of Products under Development for Breast Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

3-V Biosciences, Inc.
4SC AG
A&G Pharmaceutical, Inc.
A. Menarini Industrie Farmaceutiche Riunite Srl
AB Science SA
AbbVie Inc.
AbGenomics International, Inc.
Ability Pharma, SL
Acceleron Pharma, Inc.
Acetylon Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.
Adaptimmune Limited
ADC Therapeutics Sarl
Aduro BioTech, Inc.
Advanced Cancer Therapeutics
Advanced Proteome Therapeutics Corporation
Advaxis, Inc.
Advenchen Laboratories, LLC
Aegis Therapeutics, LLC
Aeglea BioTherapeutics, Inc.
Aerpio Therapeutics, Inc.
Aeterna Zentaris Inc.
Affichem SA
Agilvax, Inc.
Aileron Therapeutics, Inc.
Alchemia Limited
Alethia Biotherapeutics Inc.
Almac Discovery Limited
Amarna Therapeutics B.V.
Ambrx, Inc.
Amgen Inc.
Ampio Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc.
AngioGenex, Inc.
Angion Biomedica Corp.
ANP Technologies, Inc.
AntiCancer, Inc.
Antigen Express, Inc.
Antoxis Limited
Aphios Corporation
arGEN-X BV
Armour Therapeutics Inc.
Arno Therapeutics, Inc.
ArQule, Inc.
Arrien Pharmaceuticals, LLC
Ascenta Therapeutics, Inc.
Ascentage Pharma Group Corporation, Ltd.
AskAt Inc.
Aslan Pharmaceuticals Pte. Ltd.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
Athenex, Inc.
ATLAB Pharma SAS
Atossa Genetics, Inc.
Aurigene Discovery Technologies Limited
Ausio Pharmaceuticals, LLC
Axelar AB
Azaya Therapeutics, Inc.
Basilea Pharmaceutica AG
Bavarian Nordic A/S
Bayer AG
BeiGene(Beijing) Co.,Ltd
BerGenBio AS
Beth Israel Deaconess Medical Center, Inc.
Bexion Pharmaceuticals, LLC.
Bio-Path Holdings, Inc.
BIOCAD
Biocon Limited
Bionomics Limited
Bionovis SA
BioNTech AG
Bioo Therapeutics
Biotecnol, Inc.
Biotest AG
Blirt S.A.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
BriaCell Therapeutics Corp.
Bristol-Myers Squibb Company
Calithera Biosciences, Inc.
Campus Technologies Freiburg GmbH
Cantex Pharmaceuticals, Inc.
CASI Pharmaceuticals Inc.
CEL-SCI Corporation
Celgene Corporation
Cellceutix Corporation
Celldex Therapeutics, Inc.
Cellectar Biosciences, Inc.
Celltrion, Inc.
Celsion Corporation
Ceronco Biosciences
Cerulean Pharma, Inc.
Champions Oncology, Inc.
ChemoCentryx, Inc.
China Grand Wuhan General Pharmaceutical Research Institute
Chipscreen Biosciences Ltd
Chugai Pharmaceutical Co., Ltd.
Clevexel Pharma SAS
Clovis Oncology, Inc.
CohBar, Inc.
Compliment Corporation
Corcept Therapeutics Incorporated
Cristal Therapeutics
Critical Outcome Technologies Inc.
Curadev Pharma Private Limited
Curadis GmbH
Curaxys, S.L.
CureFAKtor Pharmaceuticals, LLC
Curis, Inc.
Cyclacel Pharmaceuticals, Inc.
CytomX Therapeutics, Inc.
CZ BioMed Corp
Daiichi Sankyo Company, Limited
Debiopharm International S.A.
Deciphera Pharmaceuticals, LLC
DEKK-TEC, Inc.
DexTech Medical AB
Digna Biotech, S.L.
DiNonA Inc.
DNA Therapeutics S.A.
Dompe Farmaceutici S.p.A.
Dongkook Pharmaceutical Co., Ltd.
DormaTarg, Inc.
Dr. Reddy's Laboratories Limited
Egenix, Inc.
EirGenix Inc.
Eisai Co., Ltd.
Eli Lilly and Company
EndoCeutics, Inc.
Endocyte, Inc.
EnGeneIC Ltd
Ensol Biosciences Inc.
EntreChem, S.L.
EOS Biosciences, Inc.
Epigen Biosciences, Inc.
Epirus Biopharmaceuticals, Inc.
Erytech Pharma SA
Esperance Pharmaceuticals, Inc.
Etubics Corporation
Eureka Therapeutics, Inc.
Evgen Pharma PLC
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
FibroStatin SL
FirstString Research, Inc.
Forendo Pharma Limited
Fortress Biotech, Inc.
G&E Herbal Biotechnology Co., Ltd.
G1 Therapeutics, Inc.
Galapagos NV
Galectin Therapeutics, Inc.
Galena Biopharma, Inc.
Galileo Research s.r.l.
Ganymed Pharmaceuticals AG
Genelux Corporation
Genenta Science s.r.l.
Genentech, Inc.
Genor BioPharma Co., Ltd.
Genoscience Pharma
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd.
Glycotope GmbH
Green Cross Corporation
GTx, Inc.
Halozyme Therapeutics, Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Heat Biologics, Inc.
HEC Pharm Co., Ltd.
Helix BioPharma Corp.
Hemispherx Biopharma, Inc.
Hetero Drugs Limited
Histogen, Inc.
Horizon Pharma Plc
Hospira, Inc.
Huabo Biopharm Co., Ltd.
Huperion Sarl
Hutchison MediPharma Limited
Ignyta, Inc.
Ildong Pharmaceutical Co., Ltd.
Immune Design Corp.
ImmuneXcite, Inc.
ImmunoFrontier, Inc.
ImmunoGen, Inc.
Immunomedics, Inc.
Immunophotonics Inc
Immunovaccine, Inc.
Immupharma Plc
IMPACT Therapeutics, Inc.
Imugene Limited
Inbiopro Solutions Pvt. Ltd.
Incanthera Ltd.
Incyte Corporation
Infinity Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
Intas Pharmaceuticals Ltd.
Intica Biomedical, Inc.
Invictus Oncology Pvt. Ltd.
Io Therapeutics, Inc.
Skip to top


Metastatic Breast Cancer - Pipeline Review, H2 2015 US$ 1,700.00 Dec, 2015 · 966 pages

Ask Your Question

Breast Cancer - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: